Prevalence of cardiac sarcoidosis in white population

Martusewicz-Boros, Magdalena; Boros, Piotr; Wiatr, Elżbieta; Zych, Jacek; Piotrowska-Kownacka, Dorota; Roszkowski‐Śliż, Kazimierz

doi:10.1097/md.0000000000004518

Cited by 29 publications

(16 citation statements)

References 42 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possibility of interaction with asymptomatic cardiac sarcoidosis needs to be considered when designing a future trial of azithromycin for sarcoidosis cough. The prevalence of occult cardiac involvement in sarcoidosis has been reported to be up to 25% as assessed using magnetic resonance imaging [ 18 ]. However, whether the presence of incidental cardiac imaging abnormalities translates into increased arrhythmia risk that could be exacerbated by macrolide therapy is unknown.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial

et al. 2020

View full text Add to dashboard Cite

BackgroundChronic cough is a distressing symptom for many people with pulmonary sarcoidosis. Continuous treatment with a macrolide antibiotic may improve cough. We aimed to assess the potential efficacy of azithromycin in patients with sarcoidosis and self-reported cough.MethodsWe did a non-controlled, open label clinical trial of azithromycin 250 mg once daily for 3 months in patients with pulmonary sarcoidosis who reported a chronic cough. The primary outcome was number of coughs in 24 h. Secondary outcomes were cough visual analog scales and quality of life measured using the Leicester Cough Questionnaire and King's Sarcoidosis Questionnaire. Safety outcomes included QTc interval on ECG. Measurements were made at baseline and after one and 3 months of treatment.ResultsAll 21 patients were white, median age 57 years, 9 males/12 females, median 3 years since diagnosis. Five were taking oral corticosteroids and none were taking other immunosuppressants. Twenty patients completed the trial. The median (range) number of coughs in 24 h was 228 (43–1950) at baseline, 122 (20–704) at 1 month, and 81 (16–414) at 3 months (p=0.002, Friedman's test). The median reduction in cough count at 3 months was 49.6%. There were improvements in all patient-reported outcomes. Azithromycin was well tolerated.ConclusionIn a non-controlled open-label trial in people with sarcoidosis who reported a chronic cough, 3 months of treatment with azithromycin led to improvements in a range of cough metrics. Azithromycin should be tested as a treatment for sarcoidosis cough in a randomised placebo-controlled trial.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Furthermore, QRS complex fragmentation, pathological Q waves (pseudo infarct pattern), ST changes and (rarely) epsilon waves can occur. These ECG findings in patients with extra cardiac sarcoidosis warrant further imaging studies to rule out cardiac sarcoidosis, with which they have shown significant association (Martusewicz-Boros et al, 2016b). Some patients are diagnosed with abnormal ECG features years after the onset of non-cardiac sarcoidosis; thus, ECG is essential for long-term follow-up.…”

Section: Electrocardiogram (Ecg) and Holter Monitoringmentioning

confidence: 93%

Cardiac sarcoidosis: diagnosis and management

Markatis¹,

Afthinos²,

Antonakis³

et al. 2020

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Sarcoidosis is a chronic inflammatory disease of unknown etiology characterized by multi-organ involvement. Endorgan disease consists of granulomatous inflammation, which if left untreated or not resolved spontaneously, leads to permanent fibrosis and end-organ dysfunction. Cardiac involvement and fibrosis in sarcoidosis occur in 5-10% of cases and is becoming increasingly diagnosed. This is due to increased clinical awareness among clinicians and new diagnostic modalities, since magnetic resonance imaging and positron-emission tomography are emerging as "gold standard'' tools replacing endomyocardial biopsy. Despite this progress, isolated cardiac sarcoidosis is difficult to differentiate from other causes of arrhythmogenic cardiomyopathy. Cardiac fibrosis leads to congestive heart failure, arrhythmias and sudden cardiac death. Immunosuppressives (mostly corticosteroids) are used for the treatment of cardiac sarcoidosis. Implantable devices like a cardioverter-defibrillator may be warranted in order to prevent sudden cardiac death. In this article current trends in the pathophysiology, diagnosis and management of cardiac sarcoidosis will be reviewed focusing on published research and latest guidelines. Lastly, a management algorithm is proposed.

show abstract

“…Echocardiogram has previously been shown in some studies to be abnormal in up to 70% of patients with CS, the most common finding being left ventricular dysfunction. 23 Other findings may include septal or wall dyskinesia 6 with valve disease related to sarcoidosis less common. 32 However, another one more recent study showed that echocardiography added to cardiac history and ECG did not change sensitivity of the initial screening strategy (68.8% vs 72.9%).…”

Section: Open Accessmentioning

confidence: 99%

“… 5 The incidence of CS is higher in Japanese patients with sarcoidosis, and it is the leading cause of sarcoid-attributed death (77%–85% in Japan). 6 The true incidence is therefore hypothesised to be in between these figures, but this is complicated as the clinical diagnosis of CS can be challenging. The disease can be difficult to both diagnose and manage; nevertheless, a significant proportion of patients with limited pulmonary involvement have a mild course with good outcome, often not requiring corticosteroids or immunosuppression treatment.…”

Section: Introductionmentioning

confidence: 99%

CASPA (CArdiac Sarcoidosis in PApworth) improving the diagnosis of cardiac involvement in patients with pulmonary sarcoidosis: protocol for a prospective observational cohort study

et al. 2020

View full text Add to dashboard Cite

IntroductionSarcoidosis is a multisystem disease, predominantly affecting the lungs but can involve the heart, resulting in cardiac sarcoidosis (CS). Patients require MRI/Positron Emission Tomography (PET) scans for diagnosis. Echocardiography, ECG and Holter monitoring may be indicative but not diagnostic alone. Patients can present late with conduction defects, heart failure or sudden death. The CASPA (CArdiac Sarcoidosis in PApworth) study protocol aims to (1) use MRI to identify CS prevalence; (2) use speckle-tracking echocardiography, signal averaged ECG and Holter monitoring to look for diagnostic pathways; and (3) identify serum proteins which may be associated with CS.Methods and analysisParticipants with pulmonary sarcoidosis (and no known cardiac disease) from Royal Papworth Hospital will have the following: cardiac MRI with late gadolinium, two-dimensional transthoracic echocardiography with speckle tracking, signal averaged ECG and 24-hour Holter monitor. They will provide a serum sample for brain natriuretic peptide levels and proteomics by liquid chromatography coupled to high-resolution mass spectrometry. All data will be collected on OpenClinica platform and analysed approximately 6 months after final patient recruitment.Ethics and disseminationThe Camden & Kings Cross Research Ethics Committee approved the protocol (REC number: 17/LO/0667). Integrated Research Approval System (IRAS) 222 720. Dissemination of findings will be via conference presentations and submitted to peer-reviewed journals.

show abstract

Prevalence of cardiac sarcoidosis in white population

Abstract: Supplemental Digital Content is available in the text

Cited by 29 publications

References 42 publications

Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial

Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial

Cardiac sarcoidosis: diagnosis and management

CASPA (CArdiac Sarcoidosis in PApworth) improving the diagnosis of cardiac involvement in patients with pulmonary sarcoidosis: protocol for a prospective observational cohort study

Contact Info

Product

Resources

About